Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Vonjo on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Vonjo (pacritinib) is a kinase inhibitor approved by the FDA under accelerated approval for the treatment of adults with intermediate or high-risk primary or secondary myelofibrosis (including post-polycythemia vera and post-essential thrombocythemia myelofibrosis) who have a platelet count below 50 x 10⁹/L.
Vonjo inhibits JAK2 and IRAK1 signaling pathways involved in the abnormal blood cell production characteristic of myelofibrosis. Unlike some other JAK inhibitors, Vonjo is specifically indicated for patients with significant thrombocytopenia (low platelet counts), a population often excluded from other myelofibrosis treatments.
Vonjo is intended for myelofibrosis patients with severe thrombocytopenia (platelet counts below 50 x 10⁹/L), a group with limited treatment options due to bleeding risk concerns with other therapies.
The recommended dose of Vonjo is 200 mg taken orally twice daily, with or without food. A reduced starting dose of 100 mg twice daily is used in patients with severe hepatic impairment.
Vonjo does not carry a formal FDA boxed warning. Unlike some other JAK inhibitors, Vonjo's current label does not carry the class-wide JAK-inhibitor boxed warning for MACE, thrombosis, malignancy, and mortality — these risks appear as standard (non-boxed) Warnings and Precautions. Patients and prescribers should be aware of the following important safety information.
Bleeding events have been reported. Vonjo should be avoided in patients with active bleeding, and treatment should be held before planned surgery.
Diarrhea is commonly reported and may require dose reduction or temporary interruption.
Vonjo should be avoided in patients with a baseline QTc greater than 480 msec, and electrolyte abnormalities should be corrected before starting treatment.
Major adverse cardiovascular events and thrombosis have been reported, particularly in patients who smoke or have other cardiovascular risk factors.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Vonjo is manufactured and marketed by Sobi, Inc. (Swedish Orphan Biovitrum). It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist confirming myelofibrosis diagnosis and platelet count. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for myelofibrosis patients with severe thrombocytopenia, Vonjo is sourced through authorized channels and imported under GDP-compliant logistics to preserve product quality throughout transit.
NPP sources Vonjo directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Vonjo should be stored at room temperature, below 30°C, in its original package to protect from light, and this condition is maintained throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile logistics to the patient's city.
Patients across India can access Vonjo through NPP's regulated import pathway, with hematology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology care coordination and documentation for Vonjo access.
Delhi's major hospitals assist patients with prescription support and documentation for Vonjo.
Bangalore's specialist network offers access coordination for eligible myelofibrosis patients seeking Vonjo.
Chennai-based hematology specialists coordinate Vonjo access alongside comprehensive myelofibrosis care.
Hyderabad's care institutions support patients pursuing Vonjo therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Vonjo.
Pune-based specialists assist with prescription support and Vonjo treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Vonjo.
Kochi's specialist units assist patients with the documentation needed for Vonjo access.
Chandigarh's care centers support Vonjo treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Vonjo access process.
Lucknow-based centers assist patients pursuing Vonjo therapy.
Bhubaneswar's institutions support access to Vonjo for eligible patients.
Guwahati's specialists help coordinate Vonjo access for patients across the Northeast.
Patients in other cities across India can also access Vonjo through NPP's nationwide coordination network.
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
